164 related articles for article (PubMed ID: 17056093)
1. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings.
Kovacs K; Horvath E; Syro LV; Uribe H; Penagos LC; Ortiz LD; Fadul CE
Hum Pathol; 2007 Jan; 38(1):185-9. PubMed ID: 17056093
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
Raverot G; Sturm N; de Fraipont F; Muller M; Salenave S; Caron P; Chabre O; Chanson P; Cortet-Rudelli C; Assaker R; Dufour H; Gaillard S; François P; Jouanneau E; Passagia JG; Bernier M; Cornélius A; Figarella-Branger D; Trouillas J; Borson-Chazot F; Brue T
J Clin Endocrinol Metab; 2010 Oct; 95(10):4592-9. PubMed ID: 20660056
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of a child with a prolactin secreting macroadenoma with temozolomide.
Felker J; Patterson B; Wrubel D; Janss A
J Pediatr Endocrinol Metab; 2016 Dec; 29(12):1413-1415. PubMed ID: 27815961
[TBL] [Abstract][Full Text] [Related]
4. Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm.
Syro LV; Uribe H; Penagos LC; Ortiz LD; Fadul CE; Horvath E; Kovacs K
Clin Endocrinol (Oxf); 2006 Oct; 65(4):552-3. PubMed ID: 16984254
[No Abstract] [Full Text] [Related]
5. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
Murakami M; Mizutani A; Asano S; Katakami H; Ozawa Y; Yamazaki K; Ishida Y; Takano K; Okinaga H; Matsuno A
Neurosurgery; 2011 Jun; 68(6):E1761-7; discussion E1767. PubMed ID: 21389894
[TBL] [Abstract][Full Text] [Related]
6. Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma.
Bilbao I; Egaña N; García C; Olaizola I
Endocrinol Diabetes Nutr; 2017 Dec; 64(10):564-566. PubMed ID: 29137963
[No Abstract] [Full Text] [Related]
7. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.
Hagen C; Schroeder HD; Hansen S; Hagen C; Andersen M
Eur J Endocrinol; 2009 Oct; 161(4):631-7. PubMed ID: 19654234
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.
Strowd RE; Salvatori R; Laterra JJ
J Oncol Pharm Pract; 2016 Jun; 22(3):517-22. PubMed ID: 25616657
[TBL] [Abstract][Full Text] [Related]
9. What causes a prolactinoma to be aggressive or to become a pituitary carcinoma?
Phillips J; East HE; French SE; Melcescu E; Hamilton RD; Nicholas WC; Fratkin JF; Parent AD; Luzardo G; Koch CA
Hormones (Athens); 2012; 11(4):477-82. PubMed ID: 23422771
[TBL] [Abstract][Full Text] [Related]
10. Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date.
Chen C; Yin S; Zhang S; Wang M; Hu Y; Zhou P; Jiang S
Medicine (Baltimore); 2017 Nov; 96(47):e8733. PubMed ID: 29381964
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.
Neff LM; Weil M; Cole A; Hedges TR; Shucart W; Lawrence D; Zhu JJ; Tischler AS; Lechan RM
Pituitary; 2007; 10(1):81-6. PubMed ID: 17285366
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of leptomeningeally metastasised pituitary carcinoma with temozolomide.
van der Vlist A; Snijders TJ; Stades AME; Spliet WGM; De Vos FYFL
Neth J Med; 2017 Dec; 75(10):451-454. PubMed ID: 29256415
[TBL] [Abstract][Full Text] [Related]
13. A novel use of temozolomide in a patient with malignant prolactinoma.
Byrne S; Karapetis C; Vrodos N
J Clin Neurosci; 2009 Dec; 16(12):1694-6. PubMed ID: 19818629
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.
Lasolle H; Cortet C; Castinetti F; Cloix L; Caron P; Delemer B; Desailloud R; Jublanc C; Lebrun-Frenay C; Sadoul JL; Taillandier L; Batisse-Lignier M; Bonnet F; Bourcigaux N; Bresson D; Chabre O; Chanson P; Garcia C; Haissaguerre M; Reznik Y; Borot S; Villa C; Vasiljevic A; Gaillard S; Jouanneau E; Assié G; Raverot G
Eur J Endocrinol; 2017 Jun; 176(6):769-777. PubMed ID: 28432119
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review.
Almalki MH; Aljoaib NN; Alotaibi MJ; Aldabas BS; Wahedi TS; Ahmad MM; Alshahrani F
Hormones (Athens); 2017 Apr; 16(2):139-149. PubMed ID: 28742502
[TBL] [Abstract][Full Text] [Related]
16. Early Recognition and Initiation of Temozolomide Chemotherapy for Refractory, Invasive Pituitary Macroprolactinoma with Long-Term Sustained Remission.
Barkhoudarian G; Palejwala SK; Ogunbameru R; Wei H; Eisenberg A; Kelly DF
World Neurosurg; 2018 Oct; 118():118-124. PubMed ID: 30031177
[TBL] [Abstract][Full Text] [Related]
17. Dopamine agonist-resistant prolactinomas.
Oh MC; Aghi MK
J Neurosurg; 2011 May; 114(5):1369-79. PubMed ID: 21214334
[TBL] [Abstract][Full Text] [Related]
18. Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma.
Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Horvath E; Rotondo F; Kovacs K
Hormones (Athens); 2009; 8(4):303-6. PubMed ID: 20045804
[TBL] [Abstract][Full Text] [Related]
19. How effective is temozolomide for treating pituitary tumours and when should it be used?
Halevy C; Whitelaw BC
Pituitary; 2017 Apr; 20(2):261-266. PubMed ID: 27581836
[TBL] [Abstract][Full Text] [Related]
20. Temozolomide: a novel treatment for pituitary carcinoma.
Lim S; Shahinian H; Maya MM; Yong W; Heaney AP
Lancet Oncol; 2006 Jun; 7(6):518-20. PubMed ID: 16750503
[No Abstract] [Full Text] [Related]
[Next] [New Search]
